AzTrials
AzTrials

Intraoperative AwarenessPhase 4NCT07513935

Comparison of Combined Dexmedetomidine and Ketamine (Ketodex) Versus Dexmedetomidine Alone in Awake Mapping for Deep Brain Stimulation: A Randomized Controlled Trial

A Phase 4 study testing Ketodex and Dexmedetomidine in people with Intraoperative Awareness, run by Ain Shams University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Adult patients undergoing awake Deep Brain Stimulation (DBS) surgery for movement disorders (e.g., Parkinson's Disease, Essential Tremor). Study groups After approved by Local Institutional Ethics Committee and obtaining written informed consent ....pt Divided in two groups Group I (KD1): (n = 12) ....patients who… Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Intraoperative Awareness
What is being tested?
Ketodex and Dexmedetomidine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteEgypt
Study dates
3 Mar 2026to 30 Sep 2026
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 18-75 years.
  • American Society of Anesthesiologists (ASA) physical status I, II, or III.
  • Ability to give informed consent and cooperate with the procedure (e.g., follow commands, perform intraoperative tasks).

Who cannot join

  • Contraindications to the study drugs (dexmedetomidine or ketamine).
  • Severe cardiac, respiratory, or hepatic disease.
  • Pre-existing psychological/psychiatric disorders that may interfere with intraoperative assessment (e.g., severe dementia, psychosis).
  • Allergy to local anesthetics.
  • Emergency surgery or previous DB
  • Electrocardiogram (ECG) showing heart block of any degree
Show all 9Show fewer
  • heart failure,
  • liver cirrhosis, thrombocytopenia and coagulopathies,
  • severe bradycardia,

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ainshams University

    Cairo

Other trials in Egypt

About this study

Adult patients undergoing awake Deep Brain Stimulation (DBS) surgery for movement disorders (e.g., Parkinson's Disease, Essential Tremor).

Study groups After approved by Local Institutional Ethics Committee and obtaining written informed consent ....pt Divided in two groups Group I (KD1): (n = 12) ....patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of dexmedetomidine (Precedex, 100 μg/ml, Hospira, USA) in a rate of 0.1-0.5 ug/kg/hour and ketamine infusion 0.1mg / kg/hr until the .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedo-analgesic when required and recorded.

Read more

Group II (D2): (n =12 ) ......patients who received (I.V.) dexmedetomidine in a dose of 0.5 μg/ kg diluted in 5-ml. normal saline followed by continuous infusion of dexmedetomidine in a rate of 0.1-0.5 μg/kg/hour (Precedex, 100μg/ml, Hospira, USA) until Sedation Scorethe .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted.... and BIS range of 50-70 will be adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedoanalgesic when required and recorded.

Anesthetic Protocol (Standardized) Monitoring Up on arrival to operating theatre, routine monitoring devices will be placed and baseline ECG, mean arterial pressure (MAP) and oxygen saturation (SpO2 ) will be recorded. Using Datexohmeda (GE Healthcare Co., USA) and continued till shifting out to the recovery room. The baseline values of H.R., mean arterial pressure (MAP), SPO2, and respiratory rate (RR) will be recorded.

  • Bispectral index (BIS) monitoring throughout whole procedure
  • Root Mean Square (RMS): The Root Mean Square (RMS) value of the recorded signal, often measured in volts, is a key parameter. A higher RMS value is often associated with entering the target nucleus, which is rich in neuronal activity.
  • Normalized RMS (NRMS): To account for variations, the RMS is often normalized (NRMS) by dividing the RMS of a segment by the average RMS of a baseline segment (e.g., the first five stable sessions). A common indicator for good signal amplitude within the STN, for example, is an average NRMS greater than 2.0.

Following 8 hours period of fasting before the procedure, peripheral I.V. line established with a 20G cannula and lactated Ringer's will be infused At a rate of 6-8ml/kg/hour and oxygen 3 l/min will be administered through a nasal cannula. During the procedure, monitoring of HR, MAP, SPO2,and RR will be recorded every 2 min for the first 10 min, thereafter every 5 min until the end of the procedure.

Premedication: A standardized dose of midazolam (e.g., 0.02 mg/kg IV) Ondansterone 4 mg iv as antiemetic

Drug Administration:

Dexmedetomidine: A loading dose (e.g., 0.5 mcg/kg over 10-15 minutes) followed by a maintenance infusion ( 0.1 to 0.5 u g/kg/hour).

this dose not affecting MER Ketamine (in Group DK): A low-dose continuous infusion (0.05mg/kg/hr to 0.25 mg/kg/hour) this dose not affecting MER started concurrently with dexmedetomidine. SO the investigators will decrease the loading dose of dexmedotomidine to 0.25 mcg /kg in group Accounting for synergitic effect Local Anesthesia: Standardized scalp block and local infiltration (e.g., lidocaine with epinephrine).

Rescue Analgesia/Sedation: Fentanyl (e.g., 25-50 \mu g IV bolus) will be used as rescue analgesia for both groups, as needed.

If agitation is refractory, an unblinded investigator member may administer a rescue sedative (e.g., propofol), which must be recorded .

Titration: Infusions will be titrated based on the patient's sedation level, using a validated scale Following the bolus doses, sedation score was assessed by anesthesiologist unaware of regime used by the Richmond Agitation-Sedation Scale (RASS) Score Term Description

  • 4 Combative Overtly combative or violent; immediate danger to staff.
  • 3 Very Agitated Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff.
  • 2 Agitated Frequent non-purposeful movement or patient-ventilator dyssynchrony.
  • 1 Restless Anxious or apprehensive but movements not aggressive or vigorous. 0 Alert and Calm Spontaneously pays attention to caregiver.
  • 1 Drowsy Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice.
  • 2 Light Sedation Briefly (less than 10 seconds) awakens with eye contact to voice.
  • 3 Moderate Sedation Any movement (but no eye contact) to voice.
  • 4 Deep Sedation No response to voice, but any movement to physical stimulation.
  • 5 Unarousable No response to voice or physical stimulation.
Being tested
Ketodex, Dexmedetomidine
Medical subject headings
Intraoperative Awareness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KetodexDrug

    Group I (KD1): (n = 12) ....patients who will receive intravenous (I.V.) ketamine in a dose of 0.25 mg/kg diluted in 5 ml normal saline plus dexmetedomidine 0.25ug/kg followed by infusion of dexmedetomidine (Precedex, 100 μg/ml, Hospira, USA) in a rate of 0.1-0.5 ug/kg/hour and ketamine infusion 0.1mg / kg/hr until the .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg will be administered intravenously as rescue sedo-analgesic when required and recorded.

  • DexmedetomidineDrug

    Group II (D2): (n =12 ) ......patients who received (I.V.) dexmedetomidine in a dose of 0.5 μg/ kg diluted in 5-ml. normal saline followed by continuous infusion of dexmedetomidine in a rate of 0.1-0.5 μg/kg/hour (Precedex, 100μg/ml, Hospira, USA) until Sedation Scorethe .RASS 0 to -1.sedation score and BIS range of 50-70 was adjusted.... and BIS range of 50-70 was adjusted. Supplementary fentanyl 25 μg was administered intravenously as rescue sedoanalgesic when required and recorded.

Study groups in NCT07513935
Study groupRoleWhat they receive
Group I (KD1Active comparatorNot described
Receives: Drug: Ketodex
Group II (D2):Active comparatorNot described
Receives: Drug: Dexmedetomidine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. • the NRMS Assessment

    Measured: perioperative period

Secondary outcomes (4)
  1. Total Rescue Analgesia

    Total dose of fentanyl (or other opioids) required during the surgery.

    Measured: perioperative period

  2. Time to Awakeness/Recovery

    Time from the end of surgery to achieve a specific RASS score (e.g., 0 or +1) or a modified Aldrete score suitable for PACU transfer.

    Measured: perioperative period

  3. Neurocognitive Assessment

    Measured: preoperative 6 hours and 24 hours postoperatively

  4. incidence of hypotension and bradycardia

    Measured: perioperative period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Apr 2026
  2. Study start3 Mar 2026
  3. Primary completion3 Sep 2026 (estimated)
  4. Study completion30 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07513935
Sponsor's protocol ID
FMASU R51/2026
Status last verified
Apr 2026
First submitted
13 Mar 2026
Last updated
7 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Ketodex and Dexmedetomidine in people with Intraoperative Awareness, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

• the NRMS Assessment (time frame: perioperative period). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in